Free Trial

Ayala Pharmaceuticals (ADXS) Stock Price, News & Analysis

+0.07 (+28.04%)
(As of 05/28/2024 ET)
Today's Range
50-Day Range
52-Week Range
11,963 shs
Average Volume
19,697 shs
Market Capitalization
$3.44 million
P/E Ratio
Dividend Yield
Price Target
ADXS stock logo

About Ayala Pharmaceuticals Stock (NASDAQ:ADXS)

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

ADXS Stock Price History

ADXS Stock News Headlines

Immunome: An Oncology Powerhouse In The Making
IMNM Oct 2024 22.500 call
IMNM Oct 2024 25.000 call
IMNM Oct 2024 25.000 put
IMNM Oct 2024 45.000 call
Ayala Pharmaceuticals Inc Ordinary Shares ADXS
Ayala Pharmaceuticals Inc (ADXS)
See More Headlines
Receive ADXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
($2.27) per share


Free Float
Market Cap
$3.44 million
Not Optionable
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Ruth Ben Yakar Ph.D. (Age 54)
    Chief Exec. Officer
  • Dr. Stela Gangrenovitch Ph.D.
    Co-Founder, Chief Scientist Officer and Director
  • Mr. Mark Gengrinovitch LLB
    Co-Founder, Chief Financial Officer and Director

ADXS Stock Analysis - Frequently Asked Questions

Should I buy or sell Ayala Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ayala Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ADXS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADXS, but not buy additional shares or sell existing shares.
View ADXS analyst ratings
or view top-rated stocks.

How have ADXS shares performed in 2024?

Ayala Pharmaceuticals' stock was trading at $0.6670 on January 1st, 2024. Since then, ADXS shares have decreased by 52.1% and is now trading at $0.3196.
View the best growth stocks for 2024 here

How were Ayala Pharmaceuticals' earnings last quarter?

Ayala Pharmaceuticals, Inc. (NASDAQ:ADXS) issued its earnings results on Tuesday, April, 16th. The company reported ($2.96) earnings per share for the quarter.

What other stocks do shareholders of Ayala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ayala Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Anavex Life Sciences (AVXL), Vistagen Therapeutics (VTGN), Novavax (NVAX), Highpower International (HPJ), OPKO Health (OPK) and Athersys (ATHX).

How do I buy shares of Ayala Pharmaceuticals?

Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADXS) was last updated on 5/29/2024 by Staff

From Our Partners